The reagent for mitigating DARZALEX® (daratumumab) interference on Sebia IF gels

DARZALEX® is a human monoclonal antibody that has been shown to provide superior clinical benefit

• As monotherapy in heavily pre-treated patients
• When combined with standard of care regimens for the treatment of multiple myeloma in patients with the earlier disease (e.g., >1 prior line of therapy).

It is well known that the newer treatments for MM that use humanized monoclonal antibodies (mAbs) can interfere with the patient's native antibodies in immunofixation tests. IF is one of the tests referenced in the IMWG guidelines to establish the diagnosis of complete response in a patient with MM.

HYDRASHIFT 2/4 daratumumab

HYDRASHIFT 2/4 daratumumab is a Sebia proprietary reagent to be used in conjunction with HYDRAGEL IF on the HYDRASYS 2 platforms. This reagent allows to distinguish daratumumab interference from endogenous M protein.

MAIN BENEFITS

• CE Mark, IVD reagent
• Direct technique, no reagent pre-treatment, no preanalytical step
• Compatible with HYDRAGEL 2IF and 4IF
• Easy-to-use and easy to implement
• Unchanged IF procedure

References